Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
AMLX Amylyx Pharmaceuticals
- 3.575
- +0.085+2.44%
Trading Mar 11 12:13 ET
316.75MMarket Cap-0.81P/E (TTM)
3.665High3.320Low360.78KVolume3.460Open3.490Pre Close1.27MTurnover0.61%Turnover RatioLossP/E (Static)88.60MShares7.27052wk High1.92P/B212.53MFloat Cap1.57552wk Low--Dividend TTM59.45MShs Float41.930Historical High--Div YieldTTM9.89%Amplitude1.575Historical Low3.513Avg Price1Lot Size
About Amylyx Pharmaceuticals Company
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Company Profile
SymbolAMLX
Company NameAmylyx Pharmaceuticals
Listing DateJan 7, 2022
Issue Price19.00
Founded2013
MarketNASDAQ
Employees123
Fiscal Year Ends12-31
Address43 Thorndike Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02141
Phone1-617-682-0917
Websitehttp://www.amylyx.com
Company Executives
- Name
- Position
- Salary
- Justin Klee
- Co-Chief Executive Officer and Director
- 7.42M
- Joshua Cohen
- Co-Chief Executive Officer and Director
- 7.42M
- Dr. Camille L. Bedrosian,M.D.
- Chief Medical Officer
- 2.37M
- James M. Frates
- Chief Financial Officer and Principal Accounting Officer
- 3.51M
- Gina M. Mazzariello
- Chief Legal Officer and General Counsel
- 3.01M
- Dr. George Mclean Milne, Jr,PhD
- Chairman of the Board
- 385.07K
- Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D.
- Director
- --
- Paul Fonteyne, M.S.
- Independent Director
- 342.12K
- Karen Firestone
- Independent Director
- 681.15K
- Daphne E. Quimi
- Independent Director
- 348.59K